MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00277-026-07028-7

Медицинская библиотека · Annals of hematology · 2026

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.

Xue Changwen, Wu Chao, Zhang Yingjin, Yang Wenyu, Zou Yao, Guo Ye, Ma Yueshen, Chen Yumei, Chen Xiaojuan, Zhu Xiaofan, Zhang Li

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

Blinatumomab (Blin) effectively eradicates measurable residual disease (MRD) in pediatric B-cell acute lymphoblastic leukemia (B-ALL), but standard 28-day regimens face high costs and compliance challenges. A phase 2 trial assessed a shortened 14-day Blin protocol in pediatric patients with newly diagnosed B-ALL who were MRD-positive (≥ 0.01%, < 5%) at the end of induction therapy (ChiCTR2100053318). This non-randomized trial included 60 pediatric patients with CD19+ B-ALL. Post-induction (day 46), the Blin-14d group (n = 30) received Blin (14-day infusion) only, while the Non-Blin-14d group (n = 30) continued standard chemotherapy. Primary endpoint: MRD complete remission (CR) rate post-Blin. Secondary endpoints: safety and long-term outcomes. After Blin-14d-therapy, all Blin-14d group (100%) achieved MRD negativity (MFC-MRD-neg) within one week. Median time to MRD negativity was shorter in Blin-14d vs. Non-Blin-14d (39 days vs. 42.5 days, p = 0.0243). Predicted 3-year OS, but not EFS, favored Blin-14d (OS 100% vs. 85.9%, p = 0.0360; EFS 73.9% vs. 71.5%, p = 0.2334). Treatment deviations occurred in 10% (Blin-14d) vs. 50% (Non-Blin-14d). Adverse events (AEs) affected 77% of Blin-14d patients, mostly grade 1-2; two had grade 3 AEs. No grade 4 or higher Blin-related events occurred. With the limitations of a non-randomized study, short-term Blin was highly effective in inducing MRD remission with a favorable safety profile, representing a promising and efficient treatment strategy for MRD-positive B-ALL.

Для цитирования: Xue Changwen, Wu Chao, Zhang Yingjin, Yang Wenyu, Zou Yao, Guo Ye, Ma Yueshen, Chen Yumei, Chen Xiaojuan, Zhu Xiaofan, Zhang Li. Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.. Annals of hematology. 2026. DOI: 10.1007/s00277-026-07028-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.